Does Humira Cause Infections?
Humira (adalimumab) suppresses the immune system by blocking tumor necrosis factor (TNF), a protein involved in inflammation. This increases infection risk, as the body fights pathogens less effectively. Clinical trials and post-marketing data show higher rates of serious infections, including tuberculosis (TB), bacterial sepsis, opportunistic infections (like fungal or viral), and reactivation of latent infections.[1][2]
Patients on Humira have a 2-4 times higher risk of serious infections compared to placebo, per pivotal trials like ARMADA and PREMIER. Real-world studies confirm this, with infection rates around 3-5% for serious cases annually.[3]
Common Infections Linked to Humira
- Upper respiratory infections: Most frequent, affecting 17-20% of users.[1]
- Serious bacterial infections: Pneumonia, cellulitis; odds ratio ~1.5-2.0 vs. non-users.[2]
- TB and fungal: Screening for latent TB is required before starting, due to reactivation risk (0.2-1% incidence).[4]
- Other: Herpes zoster (shingles), histoplasmosis in endemic areas.
How Does Humira Increase Infection Risk?
It inhibits TNF-alpha, crucial for recruiting immune cells to infection sites. This effect is dose-dependent and cumulative with longer use or combination therapy (e.g., with methotrexate).[3] Risk rises in the elderly, diabetics, or those with prior infections.
Testing and Prevention Before Starting
Doctors screen for TB (via skin test or interferon-gamma release assay), hepatitis B/C, and recent infections. Live vaccines are contraindicated; inactivated ones are safer post-treatment.[4] Prophylaxis like antibiotics may be used in high-risk cases.
What If You Get an Infection on Humira?
Stop treatment if serious infection occurs, per FDA labeling. Monitor for signs like fever, cough, or wounds. Hospitalization rates for infections are 20-30% higher in TNF inhibitors users.[2] Recovery often requires antibiotics or antifungals, with Humira restart only after clearance.
Comparisons to Other Biologics
Humira's infection risk is similar to other TNF blockers like Enbrel (etanercept) or Remicade (infliximab), but slightly higher than IL-17 inhibitors like Cosentyx in head-to-head trials.[5] Biosimilars (e.g., Amjevita) carry identical warnings.
| Drug | Serious Infection Rate (per 100 patient-years) |
|------|-----------------------------------------------|
| Humira | 3.8-4.5 [3] |
| Enbrel | 3.2-4.0 [5] |
| Stelara (IL-12/23 blocker) | 2.5-3.0 [5] |
Long-Term Risks and When to Worry
Risk plateaus after 1-2 years but persists; cumulative exposure over 5+ years doubles odds of hospitalization.[3] No direct cancer causation, but infections can indirectly raise lymphoma risk in predisposed patients. Discontinue if hospitalized for infection.
[1]: Humira Prescribing Information, AbbVie (FDA-approved label). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s400lbl.pdf
[2]: Keystone et al., Arthritis Rheum 2004 (ARMADA trial).
[3]: Bongartz et al., JAMA 2006 (meta-analysis of TNF inhibitors).
[4]: CDC Guidelines on TNF Inhibitors. https://www.cdc.gov/tb/publications/factsheets/adults/humira.htm
[5]: Papp et al., Lancet 2017 (VOCAL study, biologic comparisons).